Ikarian Capital, LLC Phathom Pharmaceuticals, Inc. Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$6.2 - $15.5 $487,010 - $1.22 Million	-78,550 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$11.55 - $20.06 $46,084 - $80,039	3,990 Added 5.35%	78,550 $1.07 Million
Q4 2021 Feb 14, 2022	SELL	$17.83 - $33.15 $445,749 - $828,750	-25,000 Reduced 25.11%	74,560 $1.47 Million
Q3 2021 Nov 15, 2021	SELL	$30.69 - $36.83 $13,503 - $16,205	-440 Reduced 0.44%	99,560 $3.2 Million
Q4 2020 Feb 12, 2021	BUY	$33.22 - $50.26 $3.32 Million - $5.03 Million	100,000 New	100,000 $3.32 Million

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $344M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.